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Dear Author,
Ebola retinal lesions in this review are described as ‘multiple, peripheral, chorioretinal scars 
with hypopigmented halos’. This description, from Varkey et al5 was a single case report. In 
our recent case-control study, ‘A Novel Retinal Finding in Ebola Survivors, Sierra Leone 
2016’4 we were unable to find any retinal lesions of this description and appearance in 82 
Ebola survivors and only one example in 105 controls using ultra-wide field retinal imaging. 
We did report a novel retinal lesion which appears specific to Ebola in 14.6% of survivors. It 
appears to have a peripapillary and/or isolated multifocal distribution following the 
anatomical pathway of the retinal ganglion cell axons implying a neuronal transmission to 
the retina. The lesions appear light grey in colour, of variable size, with surrounding retinal 
darkening in many cases. Their shape is variable but the presence of linear margins with 
sharp angulations in keeping with the photoreceptor triangular mosaic arrangement 
appears specific. OCT analysis demonstrates these lesions are limited to the retinal layers 
with no choroidal involvement. In all cases, we found they spare the fovea and therefore are 
not directly responsible for visual acuity deficits in the absence of intraocular inflammation. 
As posterior uveitis secondary to Ebola has previously been based on case series,1,3 many 
retinal lesions seen in survivors may have falsely been attributed to Ebola when in fact they 
are common in the local West African population. Treatment for Ebola retinal lesions alone 
with periocular or systemic steroids may not be indicated or efficacious given the good 
visual outcome of Ebola survivors with multiple retinal lesions in the absence of cataract 
formation and may be detrimental in cases of inadvertent toxoplasmosis misdiagnosis which 
is a far more common cause of retinitis in West Africa2.
 
In the final paragraph, it is stated one of the complications of posterior uveitis is recurrence 
of anterior uveitis. PCR confirmed anterior uveitis secondary to Ebola virus can occur in the 
convalescent period6 but although reoccurrences have been reported up to 13 months by 
Hereth Hébert et al1, no aqueous humour PCR analysis was conducted to enable 
confirmation. As only one of the nine figures in this publication were consistent with our 
description of Ebola retinal lesions, an alternative aetiology for the uveitis reoccurrence is 
more likely.
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